VECTOR PLUS 16025 Israël - Engels - Ministry of Health

vector plus 16025

unipharm ltd, israel - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

VECTOR PLUS 16012.5 Israël - Engels - Ministry of Health

vector plus 16012.5

unipharm ltd, israel - hydrochlorothiazide; valsartan - tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

SANDIMMUN  NEORAL  25 MG CAPSULES Israël - Engels - Ministry of Health

sandimmun neoral 25 mg capsules

novartis israel ltd - ciclosporin - capsules - ciclosporin 25 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

SANDIMMUN  NEORAL  50 MG CAPSULES Israël - Engels - Ministry of Health

sandimmun neoral 50 mg capsules

novartis israel ltd - ciclosporin - capsules - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

SANDIMMUN  NEORAL  100 MG CAPSULES Israël - Engels - Ministry of Health

sandimmun neoral 100 mg capsules

novartis israel ltd - ciclosporin - capsules - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

SANDIMMUN NEORAL 100 MGML ORAL SOLUTION Israël - Engels - Ministry of Health

sandimmun neoral 100 mgml oral solution

novartis israel ltd - ciclosporin - solution - ciclosporin 100 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment.atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

VECTOR PLUS 16012.5 Israël - Engels - Ministry of Health

vector plus 16012.5

unipharm ltd, israel - hydrochlorothiazide; valsartan - tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

VECTOR PLUS 16025 Israël - Engels - Ministry of Health

vector plus 16025

unipharm ltd, israel - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan - for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

VECTOR PLUS 8012.5 Israël - Engels - Ministry of Health

vector plus 8012.5

unipharm ltd, israel - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan - for the treatment of hypertension for patients in whom combination therapy is appropriate.

SANDIMMUN  NEORAL  100 MG CAPSULES Israël - Engels - Ministry of Health

sandimmun neoral 100 mg capsules

novartis israel ltd - ciclosporin - capsules - ciclosporin 100 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.